Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis

被引:100
作者
Takeda, Shuso [2 ]
Misawa, Koichiro [1 ]
Yamamoto, Ikuo [3 ]
Watanabe, Kazuhito [1 ,2 ]
机构
[1] Hokuriku Univ, Fac Pharmaceut Sci, Dept Hyg Chem, Kanazawa, Ishikawa 9201181, Japan
[2] Hokuriku Univ, Org Frontier Res Prevent Pharmaceut Sci, Kanazawa, Ishikawa 9201181, Japan
[3] Kyushu Univ Hlth & Welf, Sch Pharmaceut Sci, Nobeoka, Japan
关键词
D O I
10.1124/dmd.108.020909
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the present study it was revealed that cannabidiolic acid ( CBDA) selectively inhibited cyclooxygenase (COX)-2 activity with an IC50 value (50% inhibition concentration) around 2 mu M, having 9-fold higher selectivity than COX-1 inhibition. In contrast, Delta(9)-tetrahydrocannabinolic acid (Delta(9)-THCA) was a much less potent inhibitor of COX-2 ( IC50 > 100 mu M). Nonsteroidal anti-inflammatory drugs containing a carboxyl group in their chemical structures such as salicylic acid are known to inhibit nonselectively both COX-1 and COX-2. CBDA and Delta(9)-THCA have a salicylic acid moiety in their structures. Thus, the structural requirements for the CBDA-mediated COX-2 inhibition were next studied. There is a structural difference between CBDA and Delta(9)-THCA; phenolic hydroxyl groups of CBDA are freed from the ring formation with the terpene moiety, although Delta(9)-THCA has dibenzopyran ring structure. It was assumed that the whole structure of CBDA is important for COX-2 selective inhibition because beta-resorcylic acid itself did not inhibit COX-2 activity. Methylation of the carboxylic acid moiety of CBDA led to disappearance of COX-2 selectivity. Thus, it was suggested that the carboxylic acid moiety in CBDA is a key determinant for the inhibition. Furthermore, the crude extract of cannabis containing mainly CBDA was shown to have a selective inhibitory effect on COX-2. Taken together, these lines of evidence in this study suggest that naturally occurring CBDA in cannabis is a selective inhibitor for COX-2.
引用
收藏
页码:1917 / 1921
页数:5
相关论文
共 32 条
[1]  
ARAMAKI H, 1968, CHEM PHARM BULL, V16, P822
[2]   PROSTAGLANDINS AND CANNABIS .2. INHIBITION OF BIOSYNTHESIS BY NATURALLY OCCURRING CANNABINOIDS [J].
BURSTEIN, S ;
LEVIN, E ;
VARANELLI, C .
BIOCHEMICAL PHARMACOLOGY, 1973, 22 (22) :2905-2910
[3]   The cannabinoid acids: Nonpsychoactive derivatives with therapeutic potential [J].
Burstein, SH .
PHARMACOLOGY & THERAPEUTICS, 1999, 82 (01) :87-96
[4]  
DEWEY WL, 1986, PHARMACOL REV, V38, P151
[5]  
DeWitt DL, 1999, MOL PHARMACOL, V55, P625
[6]   ANALGESIC AND ANTIINFLAMMATORY ACTIVITY OF CONSTITUENTS OF CANNABIS-SATIVA L [J].
FORMUKONG, EA ;
EVANS, AT ;
EVANS, FJ .
INFLAMMATION, 1988, 12 (04) :361-371
[7]   Cyclooxygenase-2 - 10 years later [J].
Hinz, B ;
Brune, K .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (02) :367-375
[8]   Characterization of celecoxib and valdecoxib binding to cyclooxygenase [J].
Hood, WF ;
Gierse, JK ;
Isakson, PC ;
Kiefer, JR ;
Kurumbail, RG ;
Seibert, K ;
Monahan, JB .
MOLECULAR PHARMACOLOGY, 2003, 63 (04) :870-877
[9]   International Union of Pharmacology. XXVII. Classification of cannabinoid receptors [J].
Howlett, AC ;
Barth, F ;
Bonner, TI ;
Cabral, G ;
Casellas, P ;
Devane, WA ;
Felder, CC ;
Herkenham, M ;
Mackie, K ;
Martin, BR ;
Mechoulam, R ;
Pertwee, RG .
PHARMACOLOGICAL REVIEWS, 2002, 54 (02) :161-202
[10]   Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons [J].
Johnson, JL ;
Wimsatt, J ;
Buckel, SD ;
Dyer, RD ;
Maddipati, KR .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1995, 324 (01) :26-34